Prospective Epidemiological Study of Metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America

You may be eligible if

• 1. Patients aged 18 years or older;
• 2. Newly diagnosed Non-Small Cell Lung Cancer (NSCLC) during the period of the study (which includes 3 months prior to site activation by LACOG, although they can have received anti-cancer treatment during that time);
• 3. Histologically or cytologically confirmed advanced NSCLC:
• 1. Stage IIIB that progressed after curative therapy (chemoradiation and/or surgery);
• 2. Stage IV metastatic disease (de novo or distant relapse)
• 4. Any NSCLC histological subtype and molecular mutation;
• 5. Any Eastern Cooperative Oncology Group (ECOG) Performance Status (0 to 4) at diagnosis;
• 6. Patients assigned by treating physician to any therapy (i.e. chemotherapy, targeted agents, immunotherapy) or palliative care;
• 7. Access to patient medical chart for data collection;
• 8. Willing and able to provide written informed consent and privacy authorization for the release of personal health information.